Publicaciones en las que colabora con Marcos González Díaz (20)

2023

  1. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

2021

  1. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

    Leukemia, Vol. 35, Núm. 8, pp. 2358-2370

2020

  1. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

2017

  1. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Leukemia, Vol. 31, Núm. 10, pp. 2094-2103

2016

  1. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

    Nature Communications, Vol. 7

  2. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

  3. Origin of Waldenstrom's macroglobulinaemia

    Best Practice and Research: Clinical Haematology, Vol. 29, Núm. 2, pp. 136-147

2015

  1. CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

    Haematologica

2014

  1. Circulating clonotypic B cells in multiple myeloma and monoclonal gammopathy of undetermined significance

    Haematologica, Vol. 99, Núm. 1, pp. 155-162

  2. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

    Leukemia, Vol. 28, Núm. 2, pp. 391-397

  3. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction

    Applied Immunohistochemistry and Molecular Morphology, Vol. 22, Núm. 10, pp. 768-773

  4. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Blood, Vol. 123, Núm. 20, pp. 3073-3079

2013

  1. Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group

    Annals of Hematology, Vol. 92, Núm. 9, pp. 1151-1179

  2. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

    British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234

  3. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728

2011

  1. Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy

    Haematologica, Vol. 96, Núm. 10, pp. 1470-1477

  2. Upregulation of dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients

    Haematologica, Vol. 96, Núm. 3, pp. 468-471

2009

  1. Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide

    Leukemia and Lymphoma, Vol. 50, Núm. 8, pp. 1283-1289

2007

  1. Antithrombin Cambridge II (A384S): An underestimated genetic risk factor for venous thrombosis

    Blood, Vol. 109, Núm. 10, pp. 4258-4263

1997

  1. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors

    Bone Marrow Transplantation, Vol. 20, Núm. 6, pp. 451-458